Medscape: Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy

June 8, 2021

Of patients with symptomatic, obstructive hypertrophic cardiomyopathy treated with the investigational oral agent mavacamten, more than twice as many, compared with placebo, had a very large improvement from baseline in their summary quality of life score after 30 weeks of treatment in a pivotal trial with 194 patients evaluable for this endpoint.

The trial's health-related quality of life assessment, the Kansas City Cardiomyopathy Questionnaire (KCCQ), also showed an average improvement of more than 9 points, compared with placebo, in summary KCCQ scores among 98 mavacamten-treated patients, and a nearly 15-point improvement from baseline that represents a "moderate to large" improvement in overall health-related quality of life, John A. Spertus, MD, Clinical Director of Outcomes Research at Saint Luke's Mid America Heart Institute, said at the annual scientific sessions of the American College of Cardiology.

Largest Drug Benefit Ever Seen in KCCQ

The 9-point average incremental improvement on mavacamten, a selective cardiac myosin inhibitor, compared with placebo-treated patients, is "the largest drug-mediated benefit we've ever observed on the KCCQ," said Spertus, who spearheaded development of the KCCQ. 

Read the full Medscape article: Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy

Related Content

KMBC: New drug shows promise for patients with common genetic heart condition
KMBC talked to Dr. John Spertus about the exciting results of the EXPLORER-HCM Trial and one participant who says it changed his life.
EXPLORER-HCM Trial shows dramatic improvements in patients with common genetic heart condition, comes after decades of no new treatments
Saint Luke’s Mid America Heart Institute announced the results of a clinical trial that will impact patient care and improve quality of life for patients suffering from the most common genetic heart condition.
Saint Luke’s Researchers Again Take Center Stage at Global Cardiology Conference
Saint Luke’s Mid America Heart Institute to share detailed trial results at American College of Cardiology Scientific Session May 15-17.